Clinical Consultations™ in Neurotrophic Keratitis (CME Monograph)
Activity Description and Purpose
Neurotrophic keratitis is a rare but potentially sight-threatening corneal degenerative disease. Early recognition of neurotrophic keratitis is important to allow appropriate treatment that will promote corneal healing and prevent progression to more extensive, permanent corneal destruction. The content of this activity is based on the proceedings of a live CME symposium that covered the pathogenesis of neurotrophic keratitis, diagnostic evaluations, and strategies for management through reviews of the literature and clinical data, discussions among corneal experts, and detailed case histories of patients with varying stages of neurotrophic keratitis.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Describe the role of corneal sensory innervation in ocular surface health
- Integrate evaluation of corneal sensitivity into assessment of ocular surface disease
- Interpret evidence of corneal healing and reinnervation in patients treated with recombinant human nerve growth factor
- Select treatment strategies for patients diagnosed with any stage of neurotrophic keratitis
|Stephen C. Pflugfelder, MD (Chair)|
Professor of Ophthalmology
James and Margaret Elkins Chair
Baylor College of Medicine
|Kendall E. Donaldson, MD, MS|
Professor of Clinical Ophthalmology
Bascom Palmer Eye Institute in Plantation
|Christopher J. Rapuano, MD|
Professor of Ophthalmology
Sidney Kimmel Medical College
Thomas Jefferson University
Chief, Cornea Service
Wills Eye Hospital
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Kendall E. Donaldson, MD, MS, is a consultant for Alcon, Allergan, Avellino, Bausch & Lomb Incorporated, Carl Zeiss Meditec, Inc, Dompé US, Inc, Eyevance, Kala Pharmaceuticals, LENSAR, LLC, Lumenis, Omeros Corporation, ScienceBased Health, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and TissueTech, Inc.
Stephen C. Pflugfelder, MD, is a consultant for Allergan, Dompé US, Inc, Kala Pharmaceuticals, KOWA Pharmaceuticals America, Inc, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, and Senju Pharmaceutical Co, Ltd; and is a contracted researcher for Dompé US, Inc, and Novartis Pharmaceuticals Corporation.
Christopher J. Rapuano, MD, is a consultant for Bio-Tissue, Celularity Inc, Dompé US, Inc, Glaukos Corporation, Kala Pharmaceuticals, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, and TearLab Corporation; is on the speakers bureau for Bio-Tissue and Dompé US, Inc; and is a contracted researcher for Glaukos Corporation.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Cheryl Guttman Krader has individual stocks or stock options in Johnson and Johnson Vision Care, Inc.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Dompé US, Inc.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC; Dompé US, Inc; EyeNet; or the American Academy of Ophthalmology.
This CME activity is copyrighted to MedEdicus LLC ©2022. All rights reserved. 258.2
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation